HotSheets 2007 January February March April May June July August September October November December January | Newsletter President’s Message: Taking Action in 2007 Feb Conf Call: "Intimacy & Prostate Cancer" Companies, Chapters Signing Up for Sneakers@Work Day New Tests of Dendreon’s Prostate Cancer Doc Moyad’s What Works and What is Worthless Column: Vitamin D—Part II Read more.. February | Newsletter President’s Message: “What Is Awareness? Special Thanks to Joe Piper The Year in Prostate Cancer: Part I of II Doc Moyad’s What Works and What is Worthless Column: Vitamin D—Part III Feb. 13th Conference Call: Intimacy & Prostate Cancer 2nd Annual Us TOO Online Auction Announced, Seeking Donated Items for Bid Read more.. March | Newsletter Survivor Rate Highest with Prostatectomy for Localized Prostate Cancer New Members for Us TOO Board of Directors The Year in Prostate Cancer, Part II Medicare Part D and Erectile Dysfunction Leading by Example PROVENGE® Granted FDA Priority Review Read more.. April | Newsletter Special Burning Issues Supplement: Highlights from the 2007 Multidisciplinary Prostate Cancer Symposium – February 21-24, 2007, Orlando, FL GPC Biotech Provides Satraplatin for Free Calcitriol with Docetaxel Boosts Survival The Year in Prostate Cancer – Part 3 Estrogen Therapy: DES (Diethylstilbestrol) Doc Moyad’s What Works and What is Worthless Column: Zinc supplementation? Read more.. May | Newsletter Special Burning Issues Supplement: Prostate cancer and incontinence: coping strategies and treatment options MRI in Managing Prostate Cancer FDA Panel Backs New Prostate Vaccine Adjuvant ADT Can “Cure” Nonmetastasized Prostate Cancer Alendronate Increases BMD in Prostate Cancer Patients Receiving ADT Doc Moyad’s What Works and What is Worthless Column—Lycopene Read more.. June | Newsletter Doc Moyad’s What Works and What is Worthless Column—Provenge® Cell Genesis Reports Phase II Results with GVAX Immunotherapy A Survivor Reviews the 2007 ASCO Prostate Cancer Symposium UCSD Researchers Report Ability to Detect Cancer at Earliest, Curable Stage New Blood Test for Prostate Cancer—Can EPCA-2 be on the Horizon? Possible New Cancer Treatment? Antifungal Drug Stops Blood Vessel Growth Read more.. July | Newsletter New AUA Prostate Cancer Guidelines FDA Requirements for Provenge® Licensure Consider Source of Localized Prostate Cancer Recommendations Dendreon Sued after Provenge’s Ok Put Off 223Radium in Hormone-Refractory Cancer Update:Outcomes with Primary Therapy for Intermediate Risk Prostate Cancer Read more.. August | Newsletter New Data from ASCO on SPARC Trial Us TOO University in Austin, Texas “A Marvelous Evening” Survivorship Care Plan Is an Important Part of Cancer Care Sneakers@ Work Day, Great Fun, Great Success F-18 Fluor Choline PET/CT Assesses Bone Metastases in Prostate Cancer New Procedure Minimizes Post-Prostatectomy Incontinence Read more.. September | Newsletter Court Sees No Right to Unapproved Drugs FDA Requests More Data on Satraplatin Hormone Inhibitor Promising For Hard-to-Treat Prostate Cancer FDA Sued Over Provenge Delay Botox for Treating Prostate Problems Doc Moyad’s “No Bogus Science” Column Friday the 13th Lucky for Prostate Pointers Read more.. October | Newsletter CMS Proposal Would Virtually Eliminate Medicare Clinical Trials Coverage Statins Fail to Cut the Androgens that Fuel Prostate Cancer Stress Management before Prostatectomy First Biomarker Discovered that Predicts Prostate Cancer Outcome Prostate Px® Test Results Published Doc Moyad’s What Works and What is Worthless Column Read more.. November | Newsletter Charity Navigator Gives Us TOO 4-Star Rating Gleason Score and Prostate Cancer Prognosis New Study Refutes Belief that Black Men Have More Aggressive Prostate Cancer Us TOO Reaches Out to Federal Employees and Military Nomogram Can Predict Life Expectancy oc Moyad’s What Works and What is Worthless Column—Ginseng Read more.. December | Newsletter Us TOO’s 2006 Annual Report Now Available New Free Kits for Newly-Diagnosed Men Survival Analysis from the SPARC Trial Us TOO University Chicago Program a Success October 30th Intimacy Teleconference a Success Biopsy Site Affects Prostate Cancer Detection Read more..